Physician profile
Jonathan G Lim
NPI 1669829909
$650.69
in general payments reported to CMS, 2019-2025
11 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $186 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $121.44 | 2023 | Ellipsys Vascular Access System |
| Calliditas Therapeutics US INC. | $104.09 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.35 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $66.36 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $60.36 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $55.46 | 2024-2025 | Jynarque |
| Amgen INC. | $46.08 | 2025 | Tavneos |
| Lilly USA, LLC | $27.37 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $27.36 | 2025 | Lokelma |
| Akebia Therapeutics INC | $25.85 | 2024 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $21.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.